Crispr Therapeutics shares tumble after significant earnings miss
Bruce Ledesma, Chief Legal and Compliance Officer at Nextracker Inc. (NASDAQ:NXT), recently sold a notable portion of his holdings in the company. According to an SEC filing, Ledesma sold 9,891 shares of common stock on February 10, 2025, with a total transaction value of approximately $455,474. The shares were sold at a weighted average price of $46.0494 per share, with prices ranging from $46.0349 to $46.0556. Following this transaction, Ledesma holds 132,374.5 shares directly. The sale was conducted under a 10b5-1 trading plan, which Ledesma adopted in September 2024.The $6.69 billion market cap company has shown strong momentum with a 25.76% year-to-date return, despite recent volatility. Trading at a P/E ratio of 13.95, InvestingPro analysis suggests the stock is currently undervalued. InvestingPro subscribers have access to 12 additional key insights about Nextracker, including detailed valuation metrics and financial health indicators.
In other recent news, Nextracker Inc. has been the subject of several analyst reports following its latest financial results. Guggenheim raised its price target for Nextracker to $62, highlighting the company’s successful cost management strategies and improved margins. Similarly, Mizuho (NYSE:MFG) Securities increased the company’s price target to $51, after Nextracker’s financial report surpassed its projections in terms of revenue and gross margin. BMO Capital Markets also adjusted its price target for Nextracker to $50, following the company’s announcement of raised earnings guidance for FY 2025.
In addition, BofA Securities increased its price target for Nextracker to $53, citing the company’s impressive third fiscal quarter of 2025 and its robust execution. Finally, Barclays (LON:BARC) upgraded Nextracker stock from Equal Weight to Overweight, raising the price target significantly from $47 to $60, following a strong third-quarter performance.
These are recent developments in Nextracker’s financial journey, which investors will likely find informative. The company’s ability to surpass earnings estimates and raise guidance has drawn positive attention from multiple analyst firms. However, it’s important to note that these are the views of the respective analyst firms and not a reflection of this article’s stance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.